Literature DB >> 33218265

Enhancing nanoparticle penetration through airway mucus to improve drug delivery efficacy in the lung.

Daiqin Chen1,2, Jinhao Liu1,3, Jerry Wu1, Jung Soo Suk1,2,3.   

Abstract

Introduction: Airway mucus gel layer serves as a key delivery barrier that limits the performance of inhaled drug delivery nanoparticles. Conventional nanoparticles are readily trapped by the airway mucus and rapidly cleared from the lung via mucus clearance mechanisms. These nanoparticles cannot distribute throughout the lung airways, long-reside in the lung and/or reach the airway epithelium. To address this challenge, strategies to enhance particle penetration through the airway mucus have been developed and proof-of-concept has been established using mucus model systems..Areas covered: In this review, we first overview the biochemical and biophysical characteristics that render the airway mucus a challenging delivery barrier. We then introduce strategies to improve particle penetration through the airway mucus. Specifically, we walk through two classes of approaches, including modification of physicochemical properties of nanoparticles and modulation of barrier properties of airway mucus.Expert opinion: State-of-the-art strategies to overcome the airway mucus barrier have been introduced and experimentally validated. However, data should be interpreted in the comprehensive context of therapeutic delivery from the site of administration to the final destination to determine clinically-relevant approaches. Further, safety should be carefully monitored, particularly when it comes to mucus-altering strategies that may perturb physiological functions of airway mucus.

Entities:  

Keywords:  Airway mucus; drug delivery; inhaled therapy; mucoadhesion; nanoparticle

Mesh:

Substances:

Year:  2020        PMID: 33218265      PMCID: PMC9479118          DOI: 10.1080/17425247.2021.1854222

Source DB:  PubMed          Journal:  Expert Opin Drug Deliv        ISSN: 1742-5247            Impact factor:   8.129


  109 in total

Review 1.  Biodegradable nanoparticles for drug and gene delivery to cells and tissue.

Authors:  Jayanth Panyam; Vinod Labhasetwar
Journal:  Adv Drug Deliv Rev       Date:  2003-02-24       Impact factor: 15.470

Review 2.  Inhaled mannitol in cystic fibrosis.

Authors:  Peter J Wills
Journal:  Expert Opin Investig Drugs       Date:  2007-07       Impact factor: 6.206

Review 3.  Barrier properties of mucus.

Authors:  Richard A Cone
Journal:  Adv Drug Deliv Rev       Date:  2008-12-16       Impact factor: 15.470

4.  Coordinated clearance of periciliary liquid and mucus from airway surfaces.

Authors:  H Matsui; S H Randell; S W Peretti; C W Davis; R C Boucher
Journal:  J Clin Invest       Date:  1998-09-15       Impact factor: 14.808

5.  Side chain variations radically alter the diffusion of poly(2-alkyl-2-oxazoline) functionalised nanoparticles through a mucosal barrier.

Authors:  Edward D H Mansfield; Victor R de la Rosa; Radoslaw M Kowalczyk; Isabelle Grillo; Richard Hoogenboom; Katy Sillence; Patrick Hole; Adrian C Williams; Vitaliy V Khutoryanskiy
Journal:  Biomater Sci       Date:  2016-08-16       Impact factor: 6.843

Review 6.  The role of mucus on drug transport and its potential to affect therapeutic outcomes.

Authors:  Xabier Murgia; Brigitta Loretz; Olga Hartwig; Marius Hittinger; Claus-Michael Lehr
Journal:  Adv Drug Deliv Rev       Date:  2017-10-26       Impact factor: 15.470

Review 7.  Recent Advancements in Using Polymers for Intestinal Mucoadhesion and Mucopenetration.

Authors:  Essi Taipaleenmäki; Brigitte Städler
Journal:  Macromol Biosci       Date:  2020-02-11       Impact factor: 4.979

Review 8.  Ion Channel Modulators in Cystic Fibrosis.

Authors:  Martina Gentzsch; Marcus A Mall
Journal:  Chest       Date:  2018-05-08       Impact factor: 9.410

9.  Dextran-protamine coated nanostructured lipid carriers as mucus-penetrating nanoparticles for lipophilic drugs.

Authors:  Ana Beloqui; María Ángeles Solinís; Anne des Rieux; Véronique Préat; Alicia Rodríguez-Gascón
Journal:  Int J Pharm       Date:  2014-04-16       Impact factor: 5.875

Review 10.  Drug delivery and nanoparticles:applications and hazards.

Authors:  Wim H De Jong; Paul J A Borm
Journal:  Int J Nanomedicine       Date:  2008
View more
  4 in total

1.  Inhaled gene therapy of preclinical muco-obstructive lung diseases by nanoparticles capable of breaching the airway mucus barrier.

Authors:  Namho Kim; Gijung Kwak; Jason Rodriguez; Alessandra Livraghi-Butrico; Xinyuan Zuo; Valentina Simon; Eric Han; Siddharth Kaup Shenoy; Nikhil Pandey; Marina Mazur; Susan E Birket; Anthony Kim; Steven M Rowe; Richard Boucher; Justin Hanes; Jung Soo Suk
Journal:  Thorax       Date:  2021-10-25       Impact factor: 9.102

Review 2.  Nanostructures for drug delivery in respiratory diseases therapeutics: Revision of current trends and its comparative analysis.

Authors:  Luis Ángel Ibarra-Sánchez; Ana Gámez-Méndez; Manuel Martínez-Ruiz; Erik Francisco Nájera-Martínez; Brando Alan Morales-Flores; Elda M Melchor-Martínez; Juan Eduardo Sosa-Hernández; Roberto Parra-Saldívar; Hafiz M N Iqbal
Journal:  J Drug Deliv Sci Technol       Date:  2022-03-05       Impact factor: 3.981

Review 3.  Inhaled siRNA Formulations for Respiratory Diseases: From Basic Research to Clinical Application.

Authors:  Yulin Fan; Zhijun Yang
Journal:  Pharmaceutics       Date:  2022-06-02       Impact factor: 6.525

Review 4.  Engineering nano-drug biointerface to overcome biological barriers toward precision drug delivery.

Authors:  Saquib Waheed; Zhibin Li; Fangyingnan Zhang; Anna Chiarini; Ubaldo Armato; Jun Wu
Journal:  J Nanobiotechnology       Date:  2022-08-31       Impact factor: 9.429

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.